Similarly to what was observed in the 4T1 model, tumor-infiltrated total CD45 + cells significantly decreased after SHP099/TNO155 treatment, while combination with PD1 antibody further decreased the percentage (Supplementary Fig. 10g). The gene discussed is PTPRC; the disease is neoplasm.